<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715699</url>
  </required_header>
  <id_info>
    <org_study_id>Treatment for IgG4-RD</org_study_id>
    <nct_id>NCT03715699</nct_id>
  </id_info>
  <brief_title>Leflunomide Treatment for IgG4-RD</brief_title>
  <official_title>Leflunomide Treatment for IgG4-RD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label randomized controlled trial aiming to investigate whether the
      efficacy and side effect of Leflunpomide plus glucocorticoid.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response of Leflunomide treatment for IgG4-RD</measure>
    <time_frame>1 year</time_frame>
    <description>Complete response rate; Partial response rate; No response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse of Leflunomide treatment for IgG4-RD</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical relapse; Serological relapse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Autoimmune Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with single glucocorticoid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Leflunomide and glucocorticoid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone and Leflunomide</intervention_name>
    <description>Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  Aged 18 to 70 years old with informed consent

          -  All patients must meet the following diagnostic criteria of IgG4RD (2011):

               1. swelling, sclerosing and inflammatory involvement of one or more organ, including
                  sclerosing pancreatitis, sialadenitis (Mikulicz disease), sclerosing cholangitis,
                  inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial
                  nephritis, hypophysitis, sclerosing dacryoadenitis, inflammatory aortic aneurysm,
                  lymphadenopathy, or other inflammatory conditions;

               2. elevated serum IgG4 (&gt;1.35 g/L);

               3. histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma
                  cell infiltration (and IgG4+ plasma cells on immunohistology when performed).
                  Patients fulfill 1)+2)+3) are diagnosed as definite IgD4RD, 1)+2): possible
                  IgG4RD; 1)+3): probable IgG4RD;

               4. exclusion of other diseases.

        Exclusion Criteria:

          -  Patients will not be included if meets any of the following criteria:

               1. Patients who were diagnosed as other autoimmune diseases;

               2. Patients who were diagnosed as malignant diseases;

               3. Pregnant and lactating women；

               4. Active infection: HIV, HCV, HBV, TB；

               5. Serious organ function failure, expected life time less than 6 months.

               6. Presenting with Mikulicz disease without other manifestations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunyun FEI</last_name>
    <phone>+8613681125226</phone>
    <email>feiyunyun2013@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yunyun Fei</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunyun Fei</last_name>
      <phone>+8613681125226</phone>
      <email>feiyunyun2013@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>October 21, 2018</last_update_submitted>
  <last_update_submitted_qc>October 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Wen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

